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Abstract: In this study, we explored expression of microRNA (miR), miR-target genes and matrix
remodelling molecules in temporal artery biopsies (TABs) from treatment-naïve patients with gi-
ant cell arteritis (GCA, n = 41) and integrated these analyses with clinical, laboratory, ultrasound
and histological manifestations of GCA. NonGCA patients (n = 4) served as controls. GCA TABs
exhibited deregulated expression of several miRs (miR-21-5p, -145-5p, -146a-5p, -146b-5p, -155-5p,
424-3p, -424-5p, -503-5p), putative miR-target genes (YAP1, PELI1, FGF2, VEGFA, KLF4) and matrix
remodelling factors (MMP2, MMP9, TIMP1, TIPM2) with key roles in Toll-like receptor signaling,
mechanotransduction and extracellular matrix biology. MiR-424-3p, -503-5p, KLF4, PELI1 and YAP1
were identified as new deregulated molecular factors in GCA TABs. Quantities of miR-146a-5p,
YAP1, PELI1, FGF2, TIMP2 and MMP9 were particularly high in histologically positive GCA TABs
with occluded temporal artery lumen. MiR-424-5p expression in TABs and the presence of facial or
carotid arteritis on ultrasound were associated with vision disturbances in GCA patients. Correla-
tive analysis of miR-mRNA quantities demonstrated a highly interrelated expression network of
deregulated miRs and mRNAs in temporal arteries and identified KLF4 as a candidate target gene of
deregulated miR-21-5p, -146a-5p and -155-5p network in GCA TABs. Meanwhile, arterial miR and
mRNA expression did not correlate with constitutive symptoms and signs of GCA, elevated markers
of systemic inflammation nor sonographic characteristics of GCA. Our study provides new insights
into GCA pathophysiology and uncovers new candidate biomarkers of vision impairment in GCA.
Keywords: giant cell arteritis; microRNA; microRNA-target genes; arterial remodelling; toll-like
receptor signaling; arterial ultrasound; vision disturbances
1. Introduction
Giant cell arteritis (GCA) is a systemic vasculitis that occurs in individuals older than
50 years and affects large- and medium-sized arteries, especially the extracranial branches
of the carotid artery and the aorta [1]. GCA is characterized by ischaemic manifestations
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such as headache, jaw claudication, visual disturbances, and limb ischemia, and is accom-
panied by symptoms and signs of systemic inflammation that include fatigue, fever, weight
loss, myalgia and increased inflammatory markers (erythrocyte sedimentation rate (ESR),
C-reactive protein (CRP) and serum amyloid A (SAA)) [2–4].
The temporal artery biopsy (TAB) showing a transmural inflammatory infiltrate
enables diagnosis of GCA [5]. Nonetheless, a histologically negative TAB does not exclude
GCA. The vascular involvement in GCA can be segmental, and the inflammatory infiltrates
are limited to adventitia in individual patients [6,7]. Since TAB is invasive, it is being
increasingly replaced by arterial imaging using different imaging modalities, particularly
colour Doppler ultrasonography of the arteries [8]. The use of ultrasound, however,
requires skilled sonographers and is not yet widespread in routine clinical practice [9].
Research, performed on TABs has contributed significantly to current understanding
of inflammatory and remodelling events in GCA arteries that ultimately lead to ischaemic
disease manifestations [10]. The current pathogenesis concept of GCA suggests initial
activation of vasa vasorum and dendritic cells in the adventitia of the affected arteries,
followed by infiltration, activation and differentiation of CD4+ T-cells into IFNγ-secreting
Th1 cells and IL-17-secreting Th17 cells. Subsequently, monocytes are recruited to the
arterial media, differentiating into macrophages and forming multinucleated giant cells [11].
Inflammatory infiltrates produce copious amounts of inflammatory cytokines, chemokines,
growth factors and proteolytic enzymes which drive local inflammatory response [12].
Arterial stromal cells, including vascular smooth muscle cells (VSMCs) and the endothelial
cells of the vasa vasorum (the outside-in concept of inflammation) [13], play a significant
role in vascular inflammation and remodelling in GCA [14]. VSMCs undergo a phenotypic
switch into highly proliferative synthetic cells [15], which are, together with macrophages,
a rich source of reactive oxygen species, matrix metalloproteinases (MMPs, particularly
MMP2 and MMP9) and growth factors (vascular endothelial growth factor (VEGF), platelet-
derived growth factor). These molecules contribute to destruction of arterial wall structures,
support progressive adventitial neovascularization and drive rapidly evolving intimal
hyperplasia and arterial occlusion [16–18]. As the final effectors of the pathogenic cascade,
VSMCs represent a candidate therapeutic target in GCA [15].
MicroRNAs (miRs) are short non-coding regulatory RNAs that influence gene expres-
sion post-transcriptionally by controlling messenger RNA (mRNA) translation and/or
inducing mRNA degradation [19]. A single miR can regulate the expression of different
target mRNAs and individual mRNAs can be targeted by many miRs [20]. While miRs
commonly negatively regulate their target genes, some miRs also act as positive regulators
of their target gene expression [21]. Additionally, miRs exert many indirect effects on gene
regulation, for example by influencing the expression of other miRs and transcriptional fac-
tors [22]. Deregulated expression of miRs and their target genes significantly contributes to
the pathogenesis of cardiovascular diseases, including different autoimmune vasculitides
(e.g., Kawasaki disease, Behcet’s disease, GCA) [23,24].
To date, two studies have investigated miR expression in TABs of GCA patients [25,26].
Croci et al. [25] measured the expression of 1209 miRs in histologically positive TABs of
GCA patients compared to TAB negative nonGCA controls. This study identified six
significantly altered miRs in TABs of GCA patients including miR-21, -146a, -146b-5p, -150,
-155, and -299-5p, suggesting a deregulation of miRs in GCA arterial lesions. GCA patients
enrolled in this study received the steroid treatment prior to TAB sampling [25]. Meanwhile,
Bolha et al. [26] studied the expression of 752 miRs in TABs from treatment-naïve GCA
patients. This study demonstrated enhanced expression of miRs promoting the synthetic
VSMC phenotype (miR-21-5p, -146a-5p, -146b-5p and -424-5p) and under-expression of
miRs promoting the contractile VSMC phenotype (miR-23b-3p, -125a-5p, -143-3p, -143-
5p, -145-3p, -145-5p, -195-5p, -365a-3p) in GCA. The authors also identified in silico the
candidate target genes of deregulated miRs, mainly involved in arterial wall remodelling
and immune system regulation [26].
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Here, we explored the expression networks of miRs, miR-target genes and matrix
remodelling genes in TABs from treatment-naïve GCA patients and linked the expression
of these molecules to clinical, ultrasound and histological features of GCA. Our study
provides new insights into GCA pathogenesis and identifies potential new biomarkers of
vision impairment in GCA.
2. Results
2.1. Patient Characteristics and Establishment of GCA Diagnosis
Our study enrolled forty-one treatment-naïve GCA patients (26/41 females, median
age 77 years, Q25–Q75 71–79 years) and four nonGCA patients (2/4 females, median
age 80 years, Q25–Q75 71–83 years). Detailed clinical, laboratory and histological char-
acteristics of GCA patients are shown in Table 1. Briefly, GCA patients presented with
variable constitutional signs and symptoms (weight loss, fatigue, fever, sweating, myal-
gias), ischaemic complications (new onset headache, jaw claudication, vision disturbances,
vision loss) and increased systemic inflammatory markers (Table 1). Systemic inflamma-
tory markers were particularly high in GCA patients with constitutional manifestations
(Figure 1A) and headache (Figure 1B). The four nonGCA patients, who presented with
variable clinical signs and symptoms that raised suspicion of GCA, were finally diagnosed
with other illnesses: ANCA vasculitis, lymphoproliferative disease, pan-arteritis nodosa
and prostate carcinoma.
Table 1. Clinical and laboratory characteristics of GCA patients.
Characteristics GCA (n = 41)
Clinical symptoms/signs, n (%)
Symptom duration (days), median (Q25–Q75) 30 (21–60)
Constitutive symptoms/signs 33/41 (81)
Fatigue 21/41 (51)
Fever 16/41 (39)




New onset headache 34/41 (83)
Jaw claudication 26/41 (63)
Visual disturbances 11/41 (27)
Permanent vision loss 7/41 (17)
Polymyalgia rheumatica 6/41 (15)
GCA relapse 10/41 (24)
Temporal artery biopsy, n (%)
Transmural inflammation 35/41 (85)
Lumen occlusion 21/41 (51)
Arterial ultrasound, n (%)
Temporal artery—halo sign 39/41 (95)
Temporal artery wall thickness (cm), median
(Q25–Q75)
0.069 (0.055–0.090)
Occipital artery 19/41 (46)
Vertebral artery 4/41 (10)
Extended cranial arteritis (≥2 arteries) 28/41 (68)
Large vessel vasculitis 8/41 (20)
Carotid artery 6/41 (15)
Subclavian artery 6/41 (15)
Axillary artery 5/41 (12)
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Table 1. Cont.
Characteristics GCA (n = 41)
Systemic inflammation markers, median
(Q25–Q75)
ESR (mm/h) 83 (69–108)
CRP (g/L) 102 (48–150)
SAA (mg/L) 294 (124–699)
Ferritin (g/L) 281 (196–525)
Fibrinogen (g/L) 6.4 (6.0–7.4)
Haptoglobin (g/L) 4.8 (3.6–5.9)
Procalcitonin (g/L) 0.07 (0.03–0.10)
Leukocytes (×109/L) 9.2 (7.8–11.5)
Thrombocytes (×109/L) 378 (325–468)
Haemoglobin (g/L) 120 (105–129)
Legend: CRP, C-reactive protein; ESR, erythrocyte sedimentation rate; GCA, giant cell arteritis; SAA, serum
amyloid A.
Figure 1. Histological, clinical and laboratory characteristics of GCA patients and nonGCA control subjects. (A,B) Differences
in systemic inflammatory markers in TAB positive GCA patients (A) with and without constitutional symptoms and signs
and (B) with and without headache. Units used to measure ESR, CRP and SAA in (A) were mm/h, g/L, mg/L, respectively.
(C) Representative HE stainings of histologically positive and negative GCA TABs and normal TABs from nonGCA subjects.
Inflammatory cell infiltrates with granulomas are present in histologically positive GCA TABs, but not histologically
negative GCA TABs and nonGCA TABs. Histologically positive GCA TABs demonstrate extensive intimal hyperplasia,
there is a marked intimal hyperplasia in histologically negative GCA TABs, while the intima is rather thin in non-GCA
TABs. (D) Representative ultrasound imaging scans of temporal arteries in GCA patients (inflamed temporal artery with
a diagnostic halo sign) and control nonGCA subjects (normal temporal artery without a halo sign) * p < 0.05; ** p < 0.01;
*** p < 0.001. Legend: ESR, erythrocyte sedimentation rate; CRP, C-reactive protein; SAA, serum amyloid A; GCA, giant cell
arteritis; HE, hematoxylin and eosin; PCT, procalcitonin; TAB, temporal artery biopsy.
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Thirty-five (85.4%) GCA patients had positive TAB histology showing a diagnostic
transmural mononuclear inflammatory cell infiltration, while TAB was negative in 14.6%
(n = 6) of GCA patients (Table 1, Figure 1C). Systemic inflammatory markers were compa-
rably high in GCA patients with positive and negative TABs (Supplementary Figure S1A).
Temporal artery lumen occlusion was present in 51% of histologically positive GCA TABs
and none of histologically negative GCA TABs (p = 0.020, Table 1, Figure 1C). The presence
of temporal artery lumen occlusion in positive GCA TABs was not associated with constitu-
tional manifestations, ischaemic complications (data not shown) nor systemic inflammatory
markers (Supplementary Figure S1B). Colour Doppler ultrasonography of temporal arteries
detected a diagnostic halo sign (Figure 1D) in thirty-three GCA patients with positive TAB
and in all GCA patients with histologically negative TAB, pointing to a GCA diagnosis in
95% of patients with suspicion of GCA (Table 1). Temporal artery thickness, as measured by
ultrasound, did not differ between GCA patients with histologically positive and negative
TABs (Supplementary Figure S1C) nor between histologically positive GCA patients with and
without lumen occlusion on TAB (Supplementary Figure S1D).
2.2. Sonographic Pattern of GCA Affected Arteries Associates with Ischaemic Complications
We performed extended ultrasound imaging of cranial (temporal, vertebral, occipital,
facial) and large noncranial (carotid, axillary, subclavian) arteries that are characteristically
affected by GCA (Table 1). Twenty-eight GCA patients (68.3%) showed extended cranial
artery involvement (≥2 affected cranial arteries) and eight GCA patients (19.5%) had
ultrasound evidence of accompanying large vessel vasculitis (Table 1). Extended cranial
and axillar arteritis associated with a higher frequency of jaw claudication and headache,
respectively, while visual disturbances occurred more often in GCA patients with facial and
carotid artery involvement (Table 2). Sonographic patterns of arterial involvement did not
associate with constitutional symptoms, increase in systemic inflammatory markers nor
with histologically measured lumen occlusion on TABs. Lack of the association between
sonographic measures of arterial thickness and histological measures of lumen occlusion
might reflect the differences in the arterial substrate assessed by these two modalities.
Additionally, histology is done on excised arteries, which can deform to a certain extent
during excision and experimental procedures.
Table 2. Analysis of differential frequencies of clinical parameters and ultrasound-based arterial
features in patients with GCA.
Headache Jaw Claudication Vision Disturbances Vision Loss
Extended cranial arteritis n.s. 0.015 n.s. n.s.
Vertebral artery n.s. n.s. n.s. n.s.
Facial artery n.s. 0.060 0.038 n.s.
Occipital artery n.s. n.s. n.s. n.s.
Large vessel vasculitis n.s. n.s. n.s. n.s.
Carotid artery 0.051 n.s. 0.035 0.051
Subclavian artery 0.051 n.s. n.s. n.s.
Axillary artery 0.028 n.s. n.s. n.s.
Statistical analysis was performed using two-tailed Fisher’s Exact Test with p-value of <0.05 considered as
statistically significant. Legend: n.s., non significant.
2.3. MiR-424-3p and miR-503-5p Are Novel Deregulated miRs in GCA TABs
Deregulated miR expression in diseased tissues may provide important insights
into pathogenic pathways and altered moleular networks. To explore whether and how
arterial pathology in GCA alters miR expression, we compared miR expression in positive
GCA TABs, negative GCA TABs and TABs from nonGCA individuals. Our analysis
included miRs that play roles in immune response and inflammation, VSMC functions and
angiogenesis [27–29], covering a range of deregulated biological pathways in GCA. We
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measured miRs that were shown as deregulated in GCA TABs in previous studies [25,26]
(miR-21-5p, -23b-5p, -125a-5p, -143-5p, 145-5p, 146a-5p, -146b-5p, -155-5p, -195-5p and
-424-5p) and added new miR candidates, including miR-17-3p, -27b-5p, 125b-5p, -126-3p,
-130a-5p, -424-3p and -503-5p. These new miR candidates were selected based on the
literature search for known miR roles in biological processes, relevant to the pathogenesis
of GCA [18,27–30].
We confirmed the deregulated expression of miR-21-5p, -145-5p, -146a-5p, -146b-5p,
-155-5p and -424-5p in positive GCA TABs (Figure 2A) compared to histologically negative
GCA TABs and/or nonGCA TABs as also shown in previous studies [25,26]. The functional
roles of deregulated miRs are described in Supplementary Table S1. The deregulation of
other previously reported miRs including miR-23b-5p, -125a-5p, -143-5p and -195-5p was
not confirmed in our study (Supplementary Figure S2A,B).
−Δ
Figure 2. Deregulated miR expression in TABs from GCA patients. (A) Differentially expressed miRs in GCA patients
with histologically positive TABs (n = 35), GCA patients with histologically negative TABs (n = 6) and TABs from nonGCA
subjects (n = 4). miR expression was calculated as negative delta Ct (−∆Ct) of individual miRs normalized to RNU48
expression. Line represents the median miR expression in each patient group. (B) Correlation between normalized
expression of miR-424-3p, -424-5p and -503-5p in TABs from GCA and nonGCA patients. (C) Matrix of Spearman’s rank
correlation coefficients between normalized miR expression across GCA (n = 41) and nonGCA (n = 4) TABs. Plotted are
miRs that were identified as deregulated in GCA TABs. p values of the correlations are provided in the Supplementary
Table S1. (D) Normalized expression of miR-146a-5p in histologically positive GCA TABs with or without temporal
artery lumen occlusion. (E) Matrix of Spearman’s rank correlation coefficients between normalized miR expression and
sonographic measurements of the temporal arterial thickness in 41 GCA patients. Plotted are miRs that were identified
as deregulated in GCA TABs. (F) Matrix of Spearman’s rank correlation coefficients between normalized miR expression
and systemic inflammation markers in 35 GCA patients with histologically positive TABs. Plotted are miRs that were
identified as deregulated in GCA TABs. p-value of <0.05 was considered as statistically significant. * p < 0.05; ** p < 0.01;
*** p < 0.001; **** p < 0.0001. Legend: CRP, C-reactive protein; ESR, erythrocyte sedimentation rate; GCA, giant cell arteritis;
HB, heamoglobin; miR, microRNA; PCT, procalcitonin; SAA, serum amyloid A; TAB, temporal artery biopsy.
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Among the measured new candidate miRs, we identified miR-424-3p as significantly
upregulated miR in histologically positive TABs from GCA patients compared to histologi-
cally negative TABs and TABs from nonGCA individuals (Figure 2A), whereas miR-503-5p
differed significantly between histologically positive and negative GCA TABs (Figure 2A).
MiRs-503 and -424 are encoded as a miR cluster in the genomic region of the long non-
coding RNA H19X gene also known as MIR503HG [31]. Our analysis showed a strong
correlation between miR-424-3p/-5p and miR-503-5p expression in GCA and nonGCA
TABs (Figure 2B). No correlation was observed between these miRs and H19X expression
(Supplementary Figure S2C). The levels of miRs-17-3p, -27b-5p, -125b-5p, -126-3p and
-130a-5p (Supplementary Figure S2A,B) and H19X (Supplementary Figure S2D) did not
differ between the patient groups.
2.4. Deregulated miRs Exhibit a Highly Interrelated Expression Signature in GCA TABs
The upregulated miRs showed a strongly interrelated expression pattern across GCA
and nonGCA TABs (Figure 2C, Supplementary Table S2), particularly miR-21-5p/146a-
5p/-155-5p and miR-21-5p/-424-3p/-424-5p. The deregulation of these miRs was observed
solely in patients with positive GCA TABs (Figure 2A). Furthermore, miR-146a-5p expres-
sion was significantly increased in positive GCA TABs exhibiting temporal artery lumen
occlusion (Figure 2D) compared to non-occluded positive GCA TABs. Deregulated miR
expression did not correlate with sonographic measurements of the temporal artery thick-
ness (Figure 2E) in GCA patients. No correlation was found between the deregulated miR
expression and eleveated systemic inflammatory markers (Figure 2F) in TAB positive GCA.
Overall, these data suggested that the local molecular or cellular factors in the arterial wall
significantly contributed to altered miR expression in GCA TABs.
2.5. Analysis of miR-Target Genes Identifies PELI1, YAP1 and KLF4 as New Deregulated Genes in
GCA TABs
Next, we explored whether target genes of derugulated miRs are differentially ex-
pressed in TABs across patient groups. Target genes of deregulated miR-21-5p, -145-5p,
146a-5p, -146b-5p, -155-5p, 424-3p/5p and -503-5p were selected based on the miRror
database [32] of experimentally validated miR-target gene pairs and literature search
(Supplementary Table S3). We focused on genes with potential relevance to GCA pathobi-
ology, including genes involved in VSMC function, angiogenesis and tissue remodelling.
Additionally, we analysed the expression of key tissue remodelling factors, specifically
MMPs 2, 9, 14 and tissue inhibitors of MMPs (TIMP 1, 2), previously shown to be al-
tered in GCA arteries [33–35]. This analysis enabled us to get insights into the arterial
wall remodelling proces in our GCA patient cohort and associate the findings with the
expression changes of miRs and their target genes in GCA TABs. Cellular origins and
functions of deregulated miR-target genes and matrix remodelling genes are described in
Supplementary Table S1.
We showed that the expression of several genes targeted by the deregulated miRs
was altered in GCA TABs compared to nonGCA TABs. Specifically, Yes-asssociated protein
1 (YAP1), Pellino E3 ubiquitin protein ligase 1 (PELI1), vascular endothelial growth factor A
(VEGFA) and fibroblast growth factor 2 (FGF2) mRNAs were significantly upregulated in
GCA patients with positive TAB compared to nonGCA controls, while the expression
of Kruppel-like factor 4 (KLF4) mRNA was downregulated in GCA patients compared to
nonGCA controls (Figure 3A). SMAD7, SMURF2, MYOCD and PDCD4 mRNA levels did
not differ significantly between the patient groups (Supplementary Figure S3A,B).
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Figure 3. Deregulated expression of miR-target genes and matrixremodelling genes in TABs from GCA patients.
(A,B) Differentially expressed (A) miR-target genes (see also Supplementary Table S3) and (B) matrix-remodelling genes
in histologically positive GCA TABs (n = 35), histologically negative GCA TABs (n = 6) and nonGCA TABs (n = 4). Gene
expression was calculated as negative delta Ct (−∆Ct) of individual mRNAs normalized to GAPDH expression. Line
represents the median mRNA expression in each patient group. Values for GCA patients with negative TABs are marked
with red. (C) Matrix of Spearman’s rank correlation coefficients between normalized expression of miR-target genes and
matrix-remodelling genes across GCA (n = 40) and nonGCA (n = 4) TABs. Plotted are mRNAs that were identified as
deregulated in GCA TABs. p values of the correlations are provided in the Supplementary Table S2. (D) STRING enrichment
analysis of functional and physical protein-protein networks of deregulated mRNAs in GCA TABs using the medium
confidence 0.400 for the minimimum required interaction score. Colour symbols indicate GCA-relevant GO biological
processes that were among the most significantly enriched (FDR < 0.05). (E) Normalized expression of miR-target genes and
matrix-remodelling genes in histologically positive GCA TABs with or without temporal artery lumen occlusion. (F) Highly
interrelated expression of deregulated miRs, miR-target genes and matrix-remodelling genes in temporal arteries from GCA
(n = 40) subjects. Matrix of Spearman’s rank correlation coefficients between normalized expression of miRs, miR-target
genes and matrix-remodelling genes across GCA (n = 40) and nonGCA (n = 4) TABs. Plotted are miRs and mRNAs that were
identified as deregulated in GCA TABs. Correlative analyses are based on Sperman’s correlation coefficients with p < 0.05
considered as statistically significant. p values of the correlations are provided in the Supplementary Table S1. * p < 0.05;
*** p < 0.001; **** p < 0.0001. Legend: YAP1, Yes-associated protein 1; PELI1, Pellino E3 ubiquitin protein ligase 1; KLF4,
Kruppel-like factor 4; VEGFA, vascular endothelial growth factor A; FGF2, fibroblast growth factor 2; TIMP, tissue inhibitor
of matrix metalloproteinase; MMP, matrix metalloproteinase; CRP, C-reactive protein; ESR, erythrocyte sedimentation rate;
GCA, giant cell arteritis; HB, heamoglobin; mRNA, messenger RNA; miR, microRNA; PCT, procalcitonin; SAA, serum
amyloid A; TA, temporal artery; TAB, temporal artery biopsy.
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The analysis of MMPs and TIMPs showed altered expression of TIMP1, TIMP2 and
MMP9 in positive GCA TABs versus control nonGCA TABs while MMP2 mRNA expression
differed between GCA TABs versus nonGCA TABs (Figure 3B), pointing to an active tissue
remodelling process in GCA temporal arteries. MMP14 mRNA did not differ significantly
across patient groups (Supplementary Figure S3A,B).
Notably, the expresion of YAP1, FGF2, TIMP1 and TIMP2 was increased also in
negative GCA TABs compared to control nonGCA TABs (Figure 3A,B), inferring that
specific transcriptional changes could occur also in GCA arterial walls devoid of transmural
immune cell infiltration.
2.6. Deregulated miR-Target Genes and Matrix Remodelling Genes Constitute an Interrelated
Gene Network in GCA Arteries
Correlating the expression of deregulated mRNAs uncovered a strongly interrelated
mRNA signature across GCA and nonGCA TABs comprising of YAP1, PELI1, FGF2, MMP9,
TIMP1 and TIMP2 mRNAs (Figure 3C, Supplementary Table S2). The interacting functional
network of these molecules was shown also by the STRING protein-protein network
analysis (Figure 3D).
Together, these findings inferred that a common inciting stimulus, an expanded
cellular population or a shared biological pathway related to arterial wall remodelling
could underlie the observed gene expression changes in GCA TABs. In line with this, the
expression of most interrelated genes was significantly higher in positive GCA TABs with
temporal artery lumen occlusion compared to non-occluded positive GCA TABs (Figure
3E). No correlations were observed between deregulated mRNA expression and arterial
wall thickness in GCA patients as measured by the ultrasound (Supplementary Figure S3C)
nor systemic inflammatory markers (Supplementary Figure S3D). These results aligned
with the lacking association between the temporal arterial wall thickness and luminal
occlusion in GCA positive TABs (Supplementary Figure S1D).
2.7. Correlative Analysis of miR-mRNA Expression Identifies KLF4 as Candidate Target Gene of
Deregulated miR Network in GCA TABs
Given the interrelated expression of deregulated miRs (Figure 2C) and mRNAs
(Figure 3C) in temporal arteries, we hypothesized that correlative analysis of miR and
mRNA expression could capture miR-mediated gene regulation but also reveal miR-mRNA
networks concertedly driving the arterial pathology in GCA.
We demonstrated an inverse correlation between KLF4 mRNA expression and several
KLF4 targeting miRs, including miR-21-5p, -146a-5p and -155-5p (Figure 3F, Supplementary
Table S3). Whereas these miRs were upregulated in GCA TABs (Figure 2A), KLF4 was down-
regulated (Figure 3A), suggesting that miRs -21-5p, -146a-5p and -155-5p might repress
arterial KLF4 expression. Certain miRs negatively regulate their target genes [21,36], but
positive regulatory effects have been described for some miR-target gene pairs [37], includ-
ing miR-21-driven PELI1 expression [38]. YAP1 and PELI1 mRNA expression correlated
positively with their targeting miRs-21-5p/-424-5p and miRs-21-5p/-155-5p (Figure 3F).
No correlations were observed between other deregulated miRs and their target genes
(Figure 3F).
The expression of deregulated genes (KLF4, PELI1, MMP2, MMP9, TIMP1, TIMP2)
often correlated with non-targeting miRs (Figure 3F) across GCA and nonGCA TABs. For
example, matrix remodelling mRNAs MMP9, TIMP1 and TIPM2 correlated with miR-21-5p,
-146a-5p, -146b-5p and -155-5p, while KLF4 mRNA expression was negatively associated
with non-targeting miR-146b-5p, -424-3p and -424-5p. These observations suggested that
alteration in these miRs and mRNAs may stem from common disease pathway or cellular
origins in GCA TABs or capture the secondary miR effects on gene expression.
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2.8. Temporal Artery Expression of miR-424-5p Is Higher in GCA Patients with
Visual Impairment
Our analyses identified an interlinked miR and mRNA expression signatures in GCA
TABs (Figures 2C and 3C,F) and showed that many of these molecules were particularly
perturbed in GCA patients with temporal artery lumen occlusion (Figures 2D and 3E).
In contrast, no associations were found between the deregulated miRs and mRNAs and
elevated markers of systemic inflammation (Figure 2F, Supplementary Figure S3D). Based
on these findings, we hypothesized that the deregulated arterial miR and mRNA expression
might correlate with ischaemic but not constitutional GCA manifestations.
To test this hypothesis we compared miR and mRNA expression in GCA patients with
and without ischaemic or constitutional manifestations. GCA patients with negative TAB
histology were excluded from this analysis given the segmential lesion nature of GCA and
the confirmed affliction of their temporal arteries with ultrasound imaging (Table 1). In line
with our hypothesis, the expression of deregulated miRs and mRNAs did not differ with
the occurrence of constitutional signs and symptoms of GCA nor the sonographic extent
and patterns of arterial involvement. However, the levels of miR-424-5p were significantly
increased in TABs from patients with visual disturbances (Figure 4). Other miRs and
mRNAs did not correlate with the ischaemic GCA manifestations.
 
Figure 4. Increased expression of miR-424-5p in histologically positive TABs from GCA patients with
vision disturbances. Normalized expression of miR-424-5p in 35 histologically positive TABs from
GCA patients with or without vision disturbances. miR expression was calculated as negative delta
Ct (−∆Ct) of individual miRs normalized to the RNU48 expression. Line represents the median miR
expression in each patient group. * p < 0.05. Legend: GCA, giant cell arteritis.
3. Discussion
Disturbed expression of miR networks contributes to gene deregulation and pathogen-
esis of human disease. In the current study, we integrated clinical, laboratory, histological
and ultrasound imaging parameters with miR and gene expression analysis of diseased
temporal arteries in treatment-naïve GCA patients. The effects of glucocorticoids on gene
and miR expression have been shown in a variety of human immune and stromal cell types,
many relevant to arterial wall pathology in GCA [39–41]. A unique access to glucocorticoid-
naïve TABs in our study is based on our health-care model where patients with suspicion
of GCA are urgently admitted to rheumatology clinic, where they undergo the diagnostic
procedure, including TAB, and initiate therapy on the day of admission. To diagnose GCA,
we used TAB (a gold standard) combined with arterial ultrasound imaging and could
Int. J. Mol. Sci. 2021, 22, 6520 11 of 19
diagnose GCA in all enrolled patients with GCA. The observed diagnostic discrepancy
between the temporal artery ultrasound and TAB histology could arise from the differential
inspected length of the affected artery, particularly given the segmental nature of arterial
lesions in GCA [6,7].
Combining clinical, imaging and molecular disease characteristic can significantly
advance stratification of patients in prognostic and therapeutic groups. In GCA, irreversible
vision damage remains the most feared acute complication and identifying GCA patients at
risk for vision damage represents a major clinical need [42,43]. Several clinical, laboratory,
histological and ultrasound imaging parameters have been associated with increased risk
of vision disturbances in GCA. These factors include advanced age, jaw claudication, the
presence of giant cells in TABs and increased stroke-risk stratification CHADS2 score [44].
Our findings demonstrated that vision impairment was more frequent in GCA patients
with sonographic signs of facial or carotid arteritis and increased temporal artery miR-424-
5p expression. Prospective studies on larger patient cohorts should validate these findings,
evaluating the potential roles of arterial ultrasound imaging and miR-424-5p expression as
predictive biomarkers for visual complications in GCA.
In the current study, we undertook a stepwise approach in analyzing perturbed miR-
target gene regulation in temporal arteries of patients with GCA. In the first step, the
deregulated miRs were identified, subsequently guiding the target gene selection. While
facilitating discovery of candidate miR-target gene interactions, this approach proved
instrumental in uncovering interrelated miR and mRNA arterial networks and identifying
new deregulated molecules in GCA TABs.
Several deregulated miRs, their gene targets and matrix remodelling genes constituted
highly interrelated arterial gene expression networks and correlated with histological
signs of arterial wall remodelling (lumen occlusion). These findings inferred considerable
alterations of the local arterial microenvironment where inflammatory cells and VSMCs
could play a potentially pivotal role [45–49]. Single cell RNA-sequencing studies and cell
type deconvolution in the bulk transcriptomic data from GCA TABs would be needed to
confidently determine the cell type-specific contributions to the identified gene expression
changes in GCA TABs in our study.
The observed elevated and highly interrelated expression of miR-21-5p, -146a-5p
and -155-5p but also miR-21-5p, -424-3p and -424-5p in GCA TABs might be linked to
the enhanced Toll-like receptor (TLR) signaling in GCA TABs [50], accompanied by an
expansion of pro-synthetic pathogenic VSMCs and loss of contractile VSMCs in diseased
arterial walls [26]. MiR-21, -146a and -155 are aberrantly increased in many autoimmune
and inflammatory diseases including rheumatoid arthritis [51,52] and psoriasis [53]. These
miRs are commonly upregulated by TLR activation and control TLR signaling via positive
and negative feedback loops. Whereas miR-155 accelerates the pro-inflammatory TLR
signaling, miR-21 and -146a serve as TLR signaling inhibitors [54]. MiR-146a represses
the expression of the downstream components (TRAF6, IRAK1) of the TLR signaling cas-
cade [55] and miR-21 increases IL-10 by inhibiting programmed cell death 4 (PDCD4) [56].
Additionally, miR-21-5p, -146a-5p and -424-5p contribute to the phenotypic switching of
VSMC towards the pathogenic synthetic cell phenotype, associated with intimal hyperpla-
sia and vascular occlusion in GCA. Deregulation of these miRs has been recently linked
to the increased arterial wall thickness and enhanced ratio between intima and media
thickness in GCA TABs [26] and we have shown an elevated expression of miR-146a-5p in
occluded histologically positive GCA TABs.
Highly correlated perturbations in PELI1-YAP1-TIMP2 mRNA expression further
supported the alterations in TLR signaling and matrix remodelling pathways in GCA
arteries. Namely, the expression of PELI1 is enhanced in response to TLR ligation and
PELI1 exhibits core regulatory roles in fine-tuning the TLR responses [57,58]. In turn,
YAP1 plays critical roles in cardiovascular diseases associated with extensive vessel wall
remodelling, including atherosclerosis [59], pulmonary hypertension [60,61] and coronary
artery restenosis following angioplasty [46] by accelerating migration of VSMC, increasing
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proliferation of VSMCs, adventitial fibroblasts and endothelial cells and driving ECM
deposition and remodelling [62,63]. Alongside PELI1 and YAP1, KLF4, miR-424-3p and
-503-5p were uncovered as new deregulated mRNAs and miRs in GCA TABs. While
this data inferred a general perturbation of the miR-424/503 cluster in GCA TABs, the
expression of their host gene H19X remained unchanged, suggesting a decoupling of
miR-424, miR-503 and H19X expression in GCA TABs. MiR-503, miR-424 and H19X can
be co-expressed, but can perform distinct functions as recently shown in pro-fibrotic skin
fibroblasts [64].
Our gene expression analyses showed that several genes, including YAP1, FGF2,
TIMP1 and TIMP2 mRNAs were deregulated in histologically negative GCA TABs com-
pared to nonGCA TABs. Given the lack of transmural inflammatory cell infiltration in
negative GCA TABs, these changes might mirror deregulation of arterial stromal cells,
caused by cell intrinsic mechanisms or extrinsic molecules, diffusing from nearby immune-
infiltrated GCA lesions or entering the arterial wall from systemic circulation. Indeed,
negative GCA TABs, albeit devoid of transmural immune cell infiltrates, can exhibit early
histological signs of arterial wall changes, reflected in an increased arterial wall thickness
and enhanced ratio of the intima/media thickness [26].
MiR-driven target gene regulation might be masked in whole tissue analyses given
the heterogeneity of cell types, varying cell type frequencies and unequal contribution
of these cell types to the total isolated tissue RNA mass. Despite these challenges, we
identified PELI1 as a candidate gene target of deregulated miR-21 [38], and KLF4 as a
potential direct gene target of a deregulated miR-21-5p, -146a-5p and -155-5p network in
temporal arteries of patients with GCA. KLF4 is one of the principal mechanosensitive
factors in vascular endothelial cells with widespread atheroprotective and vascular homeo-
static effects [49,65,66]. The exposure of endothelial cells to laminar flow could upregulate
KLF4, while downregulating YAP1 [67]. Furthermore, the mutually inhibitory YAP1-KLF4
interactions were shown to be critical for maintaining the homeostasis of skin [68]. Our re-
sults point to upregulated YAP1 and downregulated KLF4 mRNAs in GCA TABs, however
whether these factors mechanistically interact in diseased arteries to drive GCA pathology
needs to be further elucidated. Furthermore, YAP1 expression corelated positively with
miR-21 levels and miR-21-driven RUNX1 repression led to elevated YAP expression in
myeloid-derived suppressor cells [69].
Our study was undertaken in a single clinical center in Slovenia, which provides a
unique access to treatment-naïve TABs, but serves only a population of 320,000 individuals
older than 50 years. Therefore, we could enroll only a small number of TABs from nonGCA
controls, which represents a limitation of our study. TAB is an invasive procedure and
can be performed only in patients with a high suspicion of GCA diagnosis due to ethical
reasons. Additionally, over the recent years, we have reached a high diagnostic accuracy
in diagnosing GCA by ultrasound, which has further decreased the frequency of TAB
in patients with suspected GCA having a negative ultrasound examination. Enrolling a
larger number of nonGCA subjects could lead to discovery of additional deregulated miRs
and mRNAs in GCA TABs that exhibit a smaller expression difference when compared to
nonGCA TABs. Nonetheless, despite a small number of nonGCA subjects, we were able to
confirm dysregulation of several miRs in GCA TABs that were identified in other studies
with a larger number of nonGCA patients.
In summary, we unraveled new deregulated miR and mRNA molecules in temporal
arteries of treatment-naïve patients with GCA and linked their deregulation to temporal
artery lumen occlusion and vision disturbances, thereby expanding the knowledge on
arterial pathology in GCA.
4. Materials and Methods
4.1. Study Design, Study Subjects and Clinical Data Collection
The current study included 45 consecutive patients who underwent a complete clinical
and laboratory examination, arterial ultrasound imaging and TAB for suspected GCA at
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the Department of Rheumatology, University Medical Centre Ljubljana, Slovenia from
January 2016 to December 2017. GCA diagnosis was established based on the 1990 clinical
and laboratory classification criteria of the American College of Rheumatology [70] in
combination with a histologically positive TAB or diagnostic halo sign on a temporal artery
colour Doppler ultrasonography scan and was confirmed in 41 out of 45 patients. Glucocor-
ticoid therapy commenced after GCA diagnosis, on the same day as TAB was performed.
Clinically, patients were examined for the presence of constitutional symptoms (fever,
weight loss, fatigue), new onset headache, jaw claudication, visual disturbances, vision loss
and signs of the large vessel involvement. The study was conducted in accordance with
the Declaration of Helsinki and was approved by the National Medical Ethics Committee
of the Republic of Slovenia (approvals #160/07/13, #99/04/15, #65/01/17). All subjects
signed the informed consent for participation in the study.
4.2. Laboratory Parameters
Among the laboratory parameters, we measured different markers of systemic in-
flammation, including leukocyte, thrombocyte counts and levels of hemoglobin in periph-
eral blood (Advia 120, Siemens, Munich, Germany), ESR (WesternGreen method, 1 h),
serum levels of CRP, PCT (ADVIA 1800 CRP and PCT assay), fibrinogen (Siemens BCS
XP with reagent Multifibren U), ferritin (ADVIA Centaur by direct chemiluminometric
technology), haptoglobin, and SAA (immunonephelometry; BN Prospec System, Siemens,
Munich, Germany).
4.3. Temporal Artery Biopsy
All patients were treatment-naïve prior to TAB and tissue collection. TAB was per-
formed under local anesthesia. The fresh biopsy material was divided into two parts,
allowing for histological analyses and gene expression measurements. Tissues used for
gene expression analyses were snap frozen in liquid nitrogen until RNA isolation. Histolog-
ical analyses were performed on formalin-fixed paraffin embedded sections stained with
H&E and evaluated by an experienced pathologist. Arterial wall inflammatory infiltrate
and arterial occlusion were scored semiquantitatively. Arterial occlusion was considered
when luminal stenosis was more than 75%.
4.4. Arterial Ultrasound Imaging
Arterial ultrasound included bilateral examination of the facial, vertebral, occipital
and temporal (common superficial artery and parietal and frontal branches) arteries, com-
mon carotid arteries, axillary arteries and subclavian arteries using the Philips US machine.
Using ultrasound, we could accurately visualize only ascendent and abdominal aorta.
Because of these limitations, we omitted aortic ultrasound examination from analyses.
The imaging was conducted in accordance with the Outcome Measures in Rheumatology
(OMERACT) definitions [71]. Briefly, arteries were examined in longitudinal and transver-
sal views with B-mode and colour Doppler examinations. Diagnosis of arteritis was based
on detection of a hypoechoic, increased intima-media thickness (a halo sign) and a positive
compression sign in temporal and facial arteries and of homogeneous intima-media com-
plex increased thickness in aortic arch arteries. Arterial wall (intima-media) thickness was
measured in the common superficial temporal artery in the segment parallel to the skin
surface, one cm distal from the point where the artery emerges from deeper tissue levels.
Measurements were performed in milimeters on the wall distal to the probe at the defined
anatomical area on longitudinal images in systole. Intima-media thickness was measured
from the luminal-intimal interface to the medial-adventitial interfaces.
4.5. RNA Isolation
3–6 mg of TAB samples (freshly stored in liquid nitrogen) were homogenized using
TissueLyser LT (Qiagen, Hilden, Germany) and stainless-steel beads (5 mm) at 50 Hz
for 5 min. Total RNA was isolated from TAB samples with RNeasy plus universal mini
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kit (Qiagen), according to the manufacturer’s instructions, and stored at −80 ◦C. The
concentration and purity of isolated RNA were assessed spectrophotometrically with
NanoDropTM 1000 (Thermo Fisher Scientific, Waltham, MA, USA).
4.6. MiR Expression Analysis
Reverse transcription was performed with TaqMan™ MicroRNA Reverse Transcription
Kit (Thermo Fisher Scientific) at the following conditions: 16 ◦C—30 min, 42 ◦C—30 min and
85 ◦C—5 min. Each 10 µL reaction volume contained 1 µL 10× Reverse Transcription Buffer,
0.67 µL Multiscribe Reverse Transriptase (50 U/µL), 0.13 µL RNAse inhibitor (20 U/µL),
0.1 µL dNTPs (100 Mm), 0.75 µL specific primers for 4 miRNA of interest, 5 µL (20 ng/µL)
total RNA template and RNAse-free water. miR expression was measured in duplicates
with quantitative real-time PCR (qPCR) analysis, using MicroAmp Optical 96-well reaction
plates (Thermo Fisher) and Applied Biosystems 7500 Real time PCR System (Thermo
Fisher). Each 10 µL reaction volume contained 5 µL 2× TaqMan Universal PCR Master Mix
(Thermo Fisher Scientific), 0.5 µL TaqMan microRNA specific primer, 3.5 µL RNAse-free
water and 1 µL (10 ng) cDNA template. PCR cycling conditions were: 95 ◦C—10 min,
followed by 40 cycles at 95 ◦C for 15 s and 60 ◦C for 1 min. Data acquisition was performed
at the end of each annealing/extension step. MiR primer assays are listed in Supplementary
Table S4. Expression of the small nucleolar RNA (RNU48) was used as endogenous control
to normalize the data. Data were analyzed with the comparative Ct method and presented
as −∆Ct between the Ct of miR of interest and the Ct of endogenous control.
4.7. MiR-Target Prediction and Selection of Target Genes
The selection of genes measured was based on identification of target genes of dereg-
ulated miRs in GCA patients using computational approach with miRror Suite 2.0. ap-
plication. MiRror integrates predictions from a dozen of miR resources that are based
on complementary algorithms into a unified statistical framework. The resources used
include TargetScan, MicroCosm implemented in miRBase, PicTar, DIANA-MicroT, PITA,
ElMMO-MirZ, miRanda-based microRNA.org, TargetRank, miRDB and TarBase. MiRror
combines the resources following a conversion of the miRs and gene targets identifiers [32].
Our p-value threshold was set to 0.05 and the minimal number of miR–target databases
was set to three. MiR-target genes were also selected based on literature search, focusing
on regulation of VSMC function.
4.8. MRNA Expression Analysis
The expression of mRNAs was measured in 35 histologically positive GCA TABs,
5 histologically negative GCA TABs and four nonGCA control TABs. One negative GCA
TAB was omitted from this analysis given the small amount of isolated RNA, sufficient
only for miR expression analysis. Reverse transcription of total RNA into cDNA was
performed in 20 µL reaction volumes, containing 2 µL GeneAmp 10x PCR Buffer II, 2.2 µL
MgCl2 (50 Mm), 4 µL dNTPs (10 Mm), 1 µL random hexamers, 0.5 µL Multiscribe Reverse
Transriptase (50 U/µL), 0.4 µL RNAse inhibitor (20 U/µL) (all Thermo Fisher Scientific),
10 µL (40 ng/µL) total RNA template and RNAse-free water. cDNA synthesis was per-
formed at 25 ◦C for 10 min followed by 30 min incubation at 48 ◦C and 5 min incubation
at 95 ◦C to heat inactivate the reverse transcriptase. qPCR analysis was performed in
duplicates on Applied Biosystems 7500 Real time PCR System (Thermo Fisher Scientific) in
MicroAmp Optical 96-well reaction plates (Thermo Fisher Scientific) using self-designed
primers (Mycrosynth, Balgach, Switzerland, Integrated DNA Technologies (IDT), Coralville,
IA, USA, Supplementary Table S5). Each 10 µL reaction volume contained 6.25 µL 2× Fast-
Start Universal SYBR Green MM (Roche, Basel, Switzerland), 0.375 µL of 10 nM forward
and reverse specific primers, 4.5 µL RNAse-free water and 1 µL (10 ng) cDNA template.
PCR cycling conditions were: 50 ◦C for 2 min and 95 ◦C for 10 min, followed by 40 cycles
at 95 ◦C for 15 s and 60 ◦C for 1 min. Data acquisition was performed at the end of each
annealing/extension step. Expression of GAPDH was used as endogenous control to
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normalize the data. Data were analysed with the comparative Ct method and presented as
negative deltaCt between the Ct of gene of interest and the Ct of endogenous control.
4.9. STRING Protein-Protein Network Analysis
The STRING Protein-Protein Interaction Networks Functional Enrichment Analysis
v11.0 [72] was used to analyse interactions between proteins of genes that were found to be
deregulated between TAB positive GCA patients and nonGCA controls. The settings used
were full network, where edges indicate both physical and functional protein associations)
and medium confidence (0.400) for minimum required interaction score.
4.10. Statistical Analysis
Statistical analysis was performed using SPSS statistical software package version 22.0
(SPSS Inc., Chicago, IL, USA) and Graph Pad Prism software 9.0 (Graphpad Software Inc.,
San Diego, CA, USA). The normality of data distribution was investigated by the Shapiro-
Wilk test. Summary statistics are expressed as mean and standard deviation or medians and
25th–75th percentiles (Q25–Q75). Statistical differences between two groups were calculated
using Mann-Whitney U-test or unpaired t-test with or without Welch’s correction for
continuous variables depending on the normality of data distribution. Multiple group
comparisons (TAB positive GCA, TAB negative GCA, nonGCA) were performed by analysis
of variance (normal distribution) or Kruskal–Wallis (distribution not normal) test with
adjustments for multiple comparisons using Dunn’s post hoc test. Fisher’s exact test
was used to test the contingency between categorical variables. For correlation analysis,
Spearman’s rank correlation coefficient was calculated. All tests were two-tailed and
p values of <0.05 were regarded as statistically significant.
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Abbreviations
GCA Giant cell arteritis
GC Glucocorticoids
TAB Temporal artery biopsy
TA Temporal artery
miR MicroRNA
qPCR Quantitative polymerase chain reaction
PELI1 Pellino E3 ubiquitin protein ligase 1
YAP1 Yes-associated protein 1
KLF4 Kruppel-like factor 4
MYOCD Myocardin
PDCD4 Programmed cell death protein 4
SMURF2 SMAD specific E3 ubiquitin protein ligase 2
MMP Matrix metalloproteinase
TIMP Tissue inhibitor of matrix metalloproteinase
FGF2 Fibroblast growth factor 2
VEGFA Vascular endothelial growth factor A
CDS Colour Doppler ultrasound examination
ESR Erythrocyte sedimentation rate
CRP C-reactive protein
SAA Serum amyloid A
VSMC Vascular smooth muscle cell
Ct Threshold cycle
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